- Home
- U S Osteonecrosis Market
U.S. Osteonecrosis Market - Industry Trends and Forecast to 2030
- Published Date: October, 2023 | Report ID: CLS-2021 | No of pages: 199 | Format:
U.S. osteonecrosis market is expected to reach USD 843,039.67 thousands by 2030 from USD 535,723.00 thousands in 2022, growing at a CAGR of 5.9% during the forecast period of 2023 to 2030.
Market Segmentation:
U.S. Osteonecrosis Market , By Disease Type (Traumatic, Non-Traumatic, And Idiopathic), Type (Diagnosis, and Treatment), Stages (Stage1, Stage2, Stage3, and Stage4), Location (Osteonecrosis Of Hip/Femoral Head Osteonecrosis, Osteonecrosis Of The Knee, Osteonecrosis Of The Shoulder, Osteonecrosis Of The Talus, Osteonecrosis Of The Lunate, Osteonecrosis Of The Scaphoid, and Others), Drug Type (Branded and Generic), Prescription (Over The Counter Drugs, and Prescribed Drugs), Gender (Male and Female), Age (Children, Adult, and Geriatric) End User (Hospitals, Specialty Clinics, Orthopaedic Clinics, Ambulatory Centers, and Others), Distribution Channel (Direct Tender and Retail Sales) - Industry Trends and Forecast to 2030
Overview of U.S. Osteonecrosis Market Dynamics :
Driver
• Increasing number of traumatic injuries
Restraint
• High cost associated with the diagnosis and treatment of osteonecrosis
Opportunity
• Advancements in medical technology for osteonecrosis
Market Players:
Some of the key market players operating in the U.S. osteonecrosis market are listed below:
• Sciegen Pharmaceuticals
• Almatica Pharma
• Dr. Reddy's Laboratories Ltd.
• Bayer AG
• Pfizer Inc.
• Haleon Group of Companies
• Zimmer Biomet
• Stryker
• Teva Pharmaceuticals USA, Inc. (Subsidiary of Teva Pharmaceutical Industries Ltd.)
• Arthrex, Inc
TABLE OF CONTENT
1 INTRODUCTION 19
1.1 OBJECTIVES OF THE STUDY 19
1.2 MARKET DEFINITION 19
1.3 OVERVIEW OF THE U.S. OSTEONECROSIS MARKET 19
1.4 LIMITATIONS 22
1.5 MARKETS COVERED 22
2 MARKET SEGMENTATION 28
2.1 MARKETS COVERED 28
2.2 GEOGRAPHICAL SCOPE 29
2.3 YEARS CONSIDERED FOR THE STUDY 29
2.4 CURRENCY AND PRICING 29
2.5 Cognate Lifesciences TRIPOD DATA VALIDATION MODEL 30
2.6 MULTIVARIATE MODELLING 33
2.7 DISEASE TYPE LIFELINE CURVE 33
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 34
2.9 Cognate Lifesciences MARKET POSITION GRID 35
2.10 MARKET END USER COVERAGE GRID 36
2.11 VENDOR SHARE ANALYSIS 37
2.12 SECONDARY SOURCES 38
2.13 ASSUMPTIONS 38
3 EXECUTIVE SUMMARY 39
4 PREMIUM INSIGHTS 42
4.1 PORTER’S FIVE FORCES 43
4.2 PESTEL ANALYSIS 44
4.3 INDUSTRY INSIGHTS 45
4.3.1 DEMOGRAPHIC TRENDS: IMAPCTS ON ALL INCIDENCE RATES 45
4.3.2 PATIENT FLOW DIAGRAM 46
4.3.3 KEY PRICING STRATEGIES 47
4.4 HEALTHCARE ECONOMY 48
4.4.1 HEALTHCARE EXPENDITURE 48
4.4.2 CAPITAL EXPENDITURE 49
4.4.3 CAPEX TRENDS 50
4.4.4 CAPEX ALLOCATION 51
4.4.5 FUNDING SOURCES 52
4.4.6 INDUSTRY BENCHMARKS 53
4.4.7 GDP RATIO IN OVERALL GDP 54
4.4.8 HEALTHCARE SYSTEM STRUCTURE 54
4.4.9 GOVERNMENT POLICIES 55
4.4.10 ECONOMIC DEVELOPMENT 56
4.5 PIPELINE ANALYSIS 57
4.6 REIMBURSEMENT FRAMEWORK 58
4.7 TECHNOLOGY ROADMAP 59
4.8 VALUE CHAIN ANALYSIS 60
5 EPIDEMIOLOGY 61
6 REGULATIONS 63
6.1 REGULATORY APPROVAL PROCESS AND PATHWAYS: 63
6.2 LICENSING AND REGISTRATION: 65
6.3 POST-MARKETING SURVEILLANCE: 65
6.4 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES: 66
7 MARKET OVERVIEW 67
7.1 DRIVERS 69
7.1.1 INCREASING NUMBER OF TRAUMATIC INJURIES 69
7.1.2 INCREASING CONSUMPTION OF STEROIDS AND RELATED DRUGS 69
7.1.3 INCREASING INCIDENCE OF OSTEONECROSIS 70
7.2 RESTRAINTS 70
7.2.1 HIGH COST ASSOCIATED WITH THE DIAGNOSIS AND TREATMENT OF OSTEONECROSIS 70
7.2.2 PROGNOSTIC AND DIAGNOSTIC CHALLENGES 71
7.3 OPPORTUNITIES 72
7.3.1 ADVANCEMENTS IN MEDICAL TECHNOLOGY FOR OSTEONECROSIS 72
7.3.2 INCREASING REIMBURSEMENTS SCENARIOS 74
7.4 CHALLENGES 75
7.4.1 AVAILABILITY OF LIMITED TREATMENT OPTIONS 75
7.4.2 CHALLENGING LONG-TERM MANAGEMENT AND FOLLOW UP 76
8 U.S. OSTEONECROSIS MARKET, BY DISEASE TYPE 77
8.1 OVERVIEW 78
8.2 TRAUMATIC 81
8.3 NON-TRAUMATIC 81
8.4 IDIOPATHIC 82
9 U.S. OSTEONECROSIS MARKET, BY TYPE 83
9.1 OVERVIEW 84
9.2 TREATMENT 87
9.2.1 SURGERY 87
9.2.1.1 CORE DECOMPRESSION 88
9.2.1.2 BONE RESHAPING (OSTEOTOMY) 88
9.2.1.3 BONE TRANSPLANT 88
9.2.1.4 JOINT REPLACEMENT THERAPY 88
9.2.1.5 STEM CELL THERAPY 88
9.2.2 MEDICATION 88
9.2.2.1 NSAIDS 89
9.2.2.1.1 IBUPROFEN 89
9.2.2.1.2 ASPIRIN 89
9.2.2.1.3 NAPROXEN 89
9.2.2.1.4 DICLOFENAC 89
9.2.2.1.5 OTHERS 89
9.2.2.2 BLOOD THINNERS 90
9.2.2.2.1 WARFARIN 90
9.2.2.2.2 HEPARIN 90
9.2.2.2.3 ENOXAPARIN 90
9.2.2.2.4 ARGATROBAN 90
9.2.2.2.5 DICOUMARAL 90
9.2.2.2.6 FONDAPARINUX 91
9.2.2.2.7 XIMELAGATRAN 91
9.2.2.3 OSTEOPOROSIS DRUGS 91
9.2.2.3.1 ALENDRONATE 91
9.2.2.3.2 RISEDRONATE 91
9.2.2.3.3 IBANDRONATE 91
9.2.2.3.4 ZOLEDRONIC ACID 92
9.2.2.3.5 DENOSUMAB 92
9.2.2.3.6 OTHERS 92
9.2.2.4 CHOLESTEROL-LOWERING DRUGS 92
9.2.2.4.1 ATORVASTATIN 92
9.2.2.4.2 PRAVASTATIN 92
9.2.2.4.3 FLUVASTATIN 93
9.2.2.4.4 ROSUVASTATIN 93
9.2.2.4.5 SIMVASTATIN 93
9.2.2.4.6 PITAVASTATIN 93
9.2.2.4.7 LOVASTATIN 93
9.2.2.5 OTHERS 93
9.2.3 PHYSICAL THERAPY 93
9.2.3.1 CRUTCHES 94
9.2.3.1.1 AXILLA CRUTCHES 94
9.2.3.1.1.1 METAL ALLOY 94
9.2.3.1.1.2 WOOD 94
9.2.3.1.1.3 CARBON OR GLASS FIBER REINFORCED COMPOSITE 95
9.2.3.1.1.4 OTHERS 95
9.2.3.1.2 ELBOW CRUTCHES 95
9.2.3.1.2.1 OPEN-CUFF ELBOW CRUTCHES 95
9.2.3.1.2.1.1 METAL ALLOY 96
9.2.3.1.2.1.2 WOOD 96
9.2.3.1.2.1.3 CARBON OR GLASS FIBER REINFORCED COMPOSITE 96
9.2.3.1.2.1.4 OTHERS 96
9.2.3.1.2.2 CLOSED-CUFF ELBOW CRUTCHES 96
9.2.3.1.2.2.1 METAL ALLOY 96
9.2.3.1.2.2.2 WOOD 97
9.2.3.1.2.2.3 CARBON OR GLASS FIBER REINFORCED COMPOSITE 97
9.2.3.1.2.2.4 OTHERS 97
9.2.3.1.3 GUTTER CRUTCHES 97
9.2.3.1.3.1 METAL ALLOY 97
9.2.3.1.3.2 WOOD 97
9.2.3.1.3.3 CARBON OR GLASS FIBER REINFORCED COMPOSITE 98
9.2.3.1.3.4 OTHERS 98
9.2.3.2 CASTING AND BRACING 98
9.2.3.2.1 NEWINGTON BRACE 98
9.2.3.2.2 TORONTO ORTHOSIS 98
9.2.3.2.3 SCOTTISH RITE ORTHOSIS 98
9.2.3.2.4 BROOMSTICK PLASTERS 99
9.2.3.2.5 BIRMINGHAM ORTHOSIS 99
9.2.3.3 OTHERS 99
9.2.3.3.1 CONVENTIONAL CALIPERS 100
9.2.3.3.2 SNYDER SLINGS 100
9.2.3.3.3 SLINGS WITH CRUTCHES 100
9.2.3.3.4 TRACTION 100
9.2.3.3.5 OTHERS 101
9.3 DIAGNOSIS 101
9.3.1 IMAGING TEST 102
9.3.1.1 MAGNETIC RESONANCE IMAGING (MRI) 102
9.3.1.1.1 CLOSED BORE 102
9.3.1.1.1.1 LOW FIELD STRENGTH 103
9.3.1.1.1.2 MID FIELD STRENGTH 103
9.3.1.1.1.3 HIGH FIELD STRENGTH 103
9.3.1.1.2 OPEN BORE 103
9.3.1.1.2.1 LOW FIELD STRENGTH 104
9.3.1.1.2.2 MID FIELD STRENGTH 104
9.3.1.1.2.3 HIGH FIELD STRENGTH 104
9.3.1.2 COMPUTED TOMOGRAPHY SCANNING 104
9.3.1.2.1 HIGH END SLICE 104
9.3.1.2.2 MID END SLICE 104
9.3.1.2.3 LOW END SLICE 105
9.3.1.2.4 CONE BEAN 105
9.3.1.3 X-RAY IMAGING 105
9.3.1.3.1 RADIOGRAPHY 105
9.3.1.3.1.1 DIGITAL IMAGING 106
9.3.1.3.1.2 FILM-BASED IMAGING 106
9.3.1.3.2 FLUOROSCOPY 106
9.3.1.3.2.1 DIGITAL IMAGING 106
9.3.1.3.2.2 FILM-BASED IMAGING 106
9.3.1.3.3 OTHERS 106
9.3.1.4 OTHERS 107
9.3.1.4.1 BONE SCAN 107
9.3.1.4.2 ULTRASOUND 107
9.3.1.4.2.1 2D ULTRASOUND 107
9.3.1.4.2.1.1 B/W ULTRASOUND 108
9.3.1.4.2.1.2 COLOURED 108
9.3.1.4.2.2 DOPPLER ULTRASOUND 108
9.3.1.4.2.2.1 B/W ULTRASOUND 108
9.3.1.4.2.2.2 COLOURED 108
9.3.1.4.2.3 3D & 4D ULTRASOUND 109
9.3.1.4.2.3.1 B/W ULTRASOUND 109
9.3.1.4.2.3.2 COLOURED 109
9.3.1.4.3 OTHERS 109
9.3.2 BIOPSY 110
9.3.2.1 NEEDLE BIOPSY 110
9.3.2.2 OPEN BIOPSY 110
9.3.2.3 OTHERS 110
9.3.3 OTHERS 110
10 U.S. OSTEONECROSIS MARKET, BY STAGES 111
10.1 OVERVIEW 112
10.2 STAGE 2 115
10.3 STAGE 3 115
10.4 STAGE 4 115
10.5 STAGE 1 116
11 U.S. OSTEONECROSIS MARKET, BY LOCATION 117
11.1 OVERVIEW 118
11.2 OSTEONECROSIS OF HIP/FEMORAL HEAD OSTEONECROSIS 121
11.2.1 TRAUMATIC 121
11.2.2 NON-TRAUMATIC 121
11.2.3 IDIOPATHIC OSTEONECROSIS 121
11.2.3.1 LEGG-CALVE-PERTHES DISEASE 122
11.2.3.1.1 TREATMENT 122
11.2.3.1.1.1 NON-SURGICAL 123
11.2.3.1.1.1.1 ANTI-INFLAMMATORY MEDICATION 123
11.2.3.1.1.1.1.1 IBUPROFEN 123
11.2.3.1.1.1.1.2 ASPIRIN 124
11.2.3.1.1.1.1.3 NAPROXEN SODIUM 124
11.2.3.1.1.1.1.4 NABUMETONE 124
11.2.3.1.1.1.1.5 OTHERS 124
11.2.3.1.1.1.2 BISPHOSPHONATES MEDICATIONS 124
11.2.3.1.1.1.2.1 ALENDRONATE 124
11.2.3.1.1.1.2.2 RISEDRONATE 125
11.2.3.1.1.1.2.3 IBANDRONATE 125
11.2.3.1.1.1.2.4 ZOLEDRONIC ACID 125
11.2.3.1.1.1.2.5 PAMIDRONATE 125
11.2.3.1.1.1.2.6 OTHERS 125
11.2.3.1.1.1.3 CRUTCHES 125
11.2.3.1.1.1.3.1 AXILLA CRUTCHES 126
11.2.3.1.1.1.3.2 ELBOW CRUTCHES 126
11.2.3.1.1.1.3.3 GUTTER CRUTCHES 126
11.2.3.1.1.1.4 CASTINGS & BRACINGS 126
11.2.3.1.1.1.4.1 NEWINGTON BRACE 126
11.2.3.1.1.1.4.2 TORONTO ORTHOSIS 126
11.2.3.1.1.1.4.3 SCOTTISH RITE ORTHOSIS 127
11.2.3.1.1.1.4.4 BROOMSTICK PLASTERS 127
11.2.3.1.1.1.4.5 BIRMINGHAM ORTHOSIS 127
11.2.3.1.1.2 SURGICAL 127
11.2.3.1.1.2.1 FEMORAL OSTEOTOMY 128
11.2.3.1.1.2.1.1 FEMORAL DEROTATION OSTEOTOMY 128
11.2.3.1.1.2.1.2 VARUS DEROTATION OSTEOTOMY 128
11.2.3.1.1.2.2 INNOMINATE OSTEOTOMY 128
11.2.3.1.1.2.2.1 SALTER (SINGLE INNOMINATE OSTEOTOMY) 129
11.2.3.1.1.2.2.2 SUTHERLAND (DOUBLE INNOMINATE OSTEOTOMY) 129
11.2.3.1.1.2.2.3 STEEL, TONNIS OR CARLOS (TRIPLE INNOMINATE OSTEOTOMY) 129
11.2.3.1.1.2.2.4 GANZ (PERIACETABULAR) 129
11.2.3.1.1.2.3 SHELF ARTHROPLASTY 129
11.2.3.1.1.2.4 OTHERS 129
11.2.3.1.2 DIAGNOSIS 130
11.2.3.1.2.1 MAGNETIC RESONANCE IMAGING (MRI) 130
11.2.3.1.2.1.1 CLOSED BORE 131
11.2.3.1.2.1.1.1 LOW FIELD STRENGTH 131
11.2.3.1.2.1.1.2 MID FIELD STRENGTH 131
11.2.3.1.2.1.1.3 HIGH FIELD STRENGTH 131
11.2.3.1.2.1.2 OPEN BORE 131
11.2.3.1.2.1.2.1 LOW FIELD STRENGTH 132
11.2.3.1.2.1.2.2 MID FIELD STRENGTH 132
11.2.3.1.2.1.2.3 HIGH FIELD STRENGTH 132
11.2.3.1.2.2 COMPUTED TOMOGRAPHY SCANNING 132
11.2.3.1.2.2.1 HIGH END SLICE 132
11.2.3.1.2.2.2 MID END SLICE 132
11.2.3.1.2.2.3 LOW END SLICE 133
11.2.3.1.2.2.4 CONE BEAN 133
11.2.3.1.2.3 X-RAY IMAGING 133
11.2.3.1.2.3.1 RADIOGRAPHY 133
11.2.3.1.2.3.1.1 DIGITAL IMAGING 133
11.2.3.1.2.3.1.2 FILM-BASED IMAGING 134
11.2.3.1.2.3.2 FLUOROSCOPY 134
11.2.3.1.2.3.2.1 DIGITAL IMAGING 134
11.2.3.1.2.3.2.2 FILM-BASED IMAGING 134
11.2.3.1.2.3.3 OTHERS 134
11.2.3.1.2.4 OTHERS 134
11.2.3.2 OTHERS 134
11.3 OSTEONECROSIS OF THE KNEE 135
11.3.1 TRAUMATIC 135
11.3.2 NON-TRAUMATIC 135
11.3.3 IDIOPATHIC OSTEONECROSIS 135
11.4 OSTEONECROSIS OF THE SHOULDER 136
11.4.1 TRAUMATIC 136
11.4.2 NON-TRAUMATIC 136
11.4.3 IDIOPATHIC OSTEONECROSIS 136
11.5 OSTEONECROSIS OF THE TALUS 137
11.5.1 TRAUMATIC 137
11.5.2 NON-TRAUMATIC 137
11.5.3 IDIOPATHIC OSTEONECROSIS 137
11.6 OSTEONECROSIS OF THE LUNATE 137
11.6.1 TRAUMATIC 138
11.6.2 NON-TRAUMATIC 138
11.6.3 IDIOPATHIC OSTEONECROSIS 138
11.7 OSTEONECROSIS OF THE SCAPHOID 139
11.7.1 TRAUMATIC 139
11.7.2 NON-TRAUMATIC 139
11.7.3 IDIOPATHIC OSTEONECROSIS 139
11.8 OTHERS 140
12 U.S. OSTEONECROSIS MARKET, BY DRUG TYPE 141
12.1 OVERVIEW 142
12.2 BRANDED 145
12.2.1 ORAL 145
12.2.1.1 TABLETS 145
12.2.1.2 CAPSULES 146
12.2.2 PARENTERAL 146
12.2.3 OTHERS 146
12.3 GENERIC 146
12.3.1 ORAL 146
12.3.1.1 TABLETS 147
12.3.1.2 CAPSULES 147
12.3.2 PARENTERAL 147
12.3.3 OTHERS 147
13 U.S. OSTEONECROSIS MARKET, BY PRESCRIPTION 148
13.1 OVERVIEW 149
13.2 PRESCRIBED DRUGS 152
13.3 OVER THE COUNTER DRUGS 152
14 U.S. OSTEONECROSIS MARKET, BY GENDER 153
14.1 OVERVIEW 154
14.2 MALE 157
14.3 FEMALE 157
15 U.S. OSTEONECROSIS MARKET, BY AGE 158
15.1 OVERVIEW 159
15.2 ADULT 162
15.3 GERIATRIC 162
15.4 CHILDREN 162
16 U.S. OSTEONECROSIS MARKET, BY END USER 163
16.1 OVERVIEW 164
16.2 HOSPITALS 167
16.2.1 PUBLIC 167
16.2.2 PRIVATE 167
16.3 ORTHOPEDIC CLINICS 167
16.4 SPECIALTY CLINICS 168
16.5 AMBULATORY CENTERS 168
16.6 OTHERS 169
17 U.S. OSTEONECROSIS MARKET, BY DISTRIBUTION CHANNEL 170
17.1 OVERVIEW 171
17.2 RETAIL SALES 174
17.2.1 HOSPITAL PHARMACY 174
17.2.2 RETAIL PHARMACY 174
17.2.3 ONLINE PHARMACY 174
17.3 DIRECT TENDER 175
18 U.S. OSTEONECROSIS MARKET, COMPANY LANDSCAPE 176
18.1 COMPANY SHARE ANALYSIS: U.S. 176
19 SWOT ANALYSIS 177
20 U.S. OSTEONECROSIS MARKET, CPS 178
20.1 TEVA PHARMACEUTICALS USA, INC. (SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.) 178
20.1.1 COMPANY SNAPSHOT 178
20.1.2 REVENUE ANALYSIS 178
20.1.3 PRODUCT PORTFOLIO 179
20.1.4 RECENT DEVELOPMENT 179
20.2 PFIZER INC. (2022) 180
20.2.1 COMPANY SNAPSHOT 180
20.2.2 REVENUE ANALYSIS 180
20.2.3 PRODUCT PORTFOLIO 181
20.2.4 RECENT DEVELOPMENT 181
20.3 BAYER AG (2022) 182
20.3.1 COMPANY SNAPSHOT 182
20.3.2 REVENUE ANALYSIS 182
20.3.3 PRODUCT PORTFOLIO 183
20.3.4 RECENT DEVELOPMENT 183
20.4 STRYKER 184
20.4.1 COMPANY SNAPSHOT 184
20.4.2 REVENUE ANALYSIS 184
20.4.3 PRODUCT PORTFOLIO 185
20.4.4 RECENT DEVELOPMENT 185
20.5 ARTHREX, INC. 186
20.5.1 COMPANY SNAPSHOT 186
20.5.2 PRODUCT PORTFOLIO 186
20.5.3 RECENT DEVELOPMENT 186
20.6 ALMATICA PHARMA 187
20.6.1 COMPANY SNAPSHOT 187
20.6.2 PRODUCT PORTFOLIO 187
20.6.3 RECENT DEVELOPMENT 187
20.7 DR. REDDY'S LABORATORIES LTD. (2022) 188
20.7.1 COMPANY SNAPSHOT 188
20.7.2 REVENUE ANALYSIS 188
20.7.3 PRODUCT PORTFOLIO 189
20.7.4 RECENT DEVELOPMENT 189
20.8 HALEON GROUP OF COMPANIES 190
20.8.1 COMPANY SNAPSHOT 190
20.8.2 REVENUE ANALYSIS 190
20.8.3 PRODUCT PORTFOLIO 191
20.8.4 RECENT DEVELOPMENT 191
20.9 SCIEGEN PHARMACEUTICALS. 192
20.9.1 COMPANY SNAPSHOT 192
20.9.2 PRODUCT PORTFOLIO 192
20.9.3 RECENT DEVELOPMENT 192
20.10 ZIMMER BIOMET 193
20.10.1 COMPANY SNAPSHOT 193
20.10.2 REVENUE ANALYSIS 193
20.10.3 PRODUCT PORTFOLIO 194
20.10.4 RECENT DEVELOPMENT 194
21 QUESTIONNAIRE 195
22 RELATED REPORTS 199
Segmentation
Short Description
U.S. Osteonecrosis Market, By Disease Type (Traumatic, Non-Traumatic, And Idiopathic), Type (Diagnosis, and Treatment), Stages (Stage1, Stage2, Stage3, and Stage4), Location (Osteonecrosis Of Hip/Femoral Head Osteonecrosis, Osteonecrosis Of The Knee, Osteonecrosis Of The Shoulder, Osteonecrosis Of The Talus, Osteonecrosis Of The Lunate, Osteonecrosis Of The Scaphoid, and Others), Drug Type (Branded and Generic), Prescription (Over The Counter Drugs, and Prescribed Drugs), Gender (Male and Female), Age ( Children, Adult, and Geriatric) End User (Hospitals, Specialty Clinics, Orthopaedic Clinics, Ambulatory Centers, and Others), Distribution Channel (Direct Tender and Retail Sales), Country (U.S..) - Industry Trends and Forecast to 2030
Market Definition
Osteonecrosis, also referred to as avascular necrosis or aseptic necrosis, is a condition characterized by the death or deterioration of bone tissue due to an inadequate blood supply. It can occur in various bones in the body, but it most commonly affects the hip joint. The compromised blood flow deprives the bone cells of essential oxygen and nutrients, leading to their death and subsequent damage to the affected bone. As a result, the bone structure weakens, becomes less able to withstand normal stress, and may eventually collapse or become deformed. Osteonecrosis can cause pain, limited range of motion, and functional impairment. Common causes of osteonecrosis include trauma, corticosteroid use, excessive alcohol consumption, certain medical conditions, and underlying factors that affect blood circulation. Early diagnosis and appropriate management are essential in preventing further bone damage and preserving joint function. Treatment options for osteonecrosis may include conservative measures to manage symptoms and slow disease progression and surgical interventions to relieve pain and restore joint function
Market Segmentation
The U.S. osteonecrosis market is segmented into ten notable segments based on disease type, type, stages, location, drug type, prescription, gender, age, end user, and distribution channel.
• On the basis of disease type, the market is segmented into traumatic, non-traumatic, and idiopathic
• On the basis of type, the market is segmented into diagnosis and treatment. The diagnosis segment is further segmented into imaging tests, biopsy, and others
• On the basis of stages, the market is segmented into stage1, stage2, stage3, and stage4
• On the basis of location, the market is segmented into osteonecrosis of hip/femoral head osteonecrosis, osteonecrosis of the knee, osteonecrosis of the shoulder, osteonecrosis of the talus, osteonecrosis of the lunate, osteonecrosis of the scaphoid, and others.
• On the basis of drug type, the market is segmented into branded and generic. The branded and generic segment is further segmented into oral, parentral, and others.
• On the basis of prescription, the market is segmented into over the counter drugs and prescribed drugs.
• On the basis of gender, the market is segmented into male and female.
• On the basis of age, the market is segmented into children, adult, and geriatric
• On the basis of end user, the market is segmented into hospitals, specialty clinics, orthopaedic clinics, ambulatory centers, and others.
• On the basis of distribution channel, the market is segmented into direct tender and retail sales
Market Players
Some of the major players operating in the U.S. osteonecrosis market are:
• Sciegen Pharmaceuticals
• Almatica Pharma
• Dr. Reddy's Laboratories Ltd.
• Bayer AG
• Pfizer Inc.
• Haleon Group of Companies
• Zimmer Biomet
• Stryker
• Teva Pharmaceuticals USA, Inc. (Subsidiary of Teva Pharmaceutical Industries Ltd.)
• Arthrex, Inc.
Methodology
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
© 2025 Cognate Lifesciences. All Rights Reserved.